BOCA RATON REGIONAL HOSPITAL

Type: Teaching hospital
Where: BOCA RATON, FL
Medicare CCN: 100168
Received: $1,191,680 in 227 records, 2019 ($316,189 general, $875,491 research)
Source: CMS Open Payments search ↗

On this site

Business registration: BOCA RATON REGIONAL HOSPITAL, INC. Fuzzy (name and state)
Nonprofit: BOCA RATON REGIONAL HOSPITAL INC Fuzzy (name and state)

By year

Program year	Kind	Records	Amount
2019	General payment	88	$316,189
2019	Research payment	139	$875,491

By company

Company	Records	Amount	Years
GE HEALTHCARE	7	$255,864	2019
Merck Sharp & Dohme LLC	45	$196,802	2019
AstraZeneca UK Limited	2	$123,323	2019
Cook Research Incorporated	3	$109,880	2019
Genentech, Inc.	15	$83,722	2019
AstraZeneca Pharmaceuticals LP	4	$76,156	2019
Eisai Inc.	26	$57,802	2019
TESARO, Inc.	3	$41,612	2019
Stryker Corporation	21	$26,289	2019
Penumbra, Inc.	2	$21,500	2019
ABBVIE INC.	8	$18,086	2019
Verastem, Inc.	3	$15,521	2019
Eli Lilly and Company	1	$13,350	2019
EMD Serono, Inc.	1	$13,349	2019
Medical Device Business Services, Inc.	3	$13,092	2019
Abbott Laboratories	13	$12,153	2019
E.R. Squibb & Sons, L.L.C.	3	$12,035	2019
Bayer Healthcare Pharmaceuticals Inc.	6	$11,883	2019
Medtronic USA, Inc.	4	$11,540	2019
Bard Peripheral Vascular, Inc.	2	$9,500	2019
Biocompatibles UK Ltd	2	$8,979	2019
Cook Incorporated	2	$8,000	2019
PFIZER INC.	3	$7,845	2019
Allergan, Inc.	2	$6,500	2019
Boehringer Ingelheim Pharmaceuticals, Inc.	2	$5,142	2019
MDD US Operations, LLC	3	$5,000	2019
Celgene Corporation	1	$4,705	2019
Clovis Oncology, Inc.	4	$3,362	2019
Endologix LLC	3	$3,022	2019
CSL Behring	3	$3,004	2019
Pacira Pharmaceuticals Incorporated	1	$1,670	2019
Orthofix Medical, Inc.	1	$1,500	2019
Novartis Pharmaceuticals Corporation	1	$1,500	2019
Amgen Inc.	1	$1,500	2019
Genentech USA, Inc.	1	$1,500	2019
Alexion Pharmaceuticals, Inc.	1	$1,500	2019
KARL STORZ Endoscopy-America	19	$1,170	2019
Chiesi USA, Inc.	1	$1,062	2019
Siemens Medical Solutions USA, Inc.	1	$750	2019
Insulet Corporation	1	$350	2019
Masimo Corporation	1	$123	2019
Cerner Corporation	1	$25	2019

By nature of payment

Nature	Records	Amount
Research payment	139	$875,491
Compensation for services other than consulting, including serving as faculty or as a speaker at a v	20	$149,594
Space rental or facility fees (teaching hospital only)	23	$53,005
Gift	23	$51,239
Education	7	$30,127
Grant	6	$22,040
Consulting Fee	4	$9,587
Food and Beverage	5	$593

Records

Date	Company	Amount	Nature	Form	Product	Study	Year
2019-12-31	Stryker Corporation	$3,021	Gift	In-kind items and services	SURG - SYSTEM 7 Device, SURGICAL		2019
2019-12-31	Stryker Corporation	$2,966	Gift	In-kind items and services	SURG - REMB Device, SURGICAL		2019
2019-12-31	Siemens Medical Solutions USA, Inc.	$750	Research payment	Cash or cash equivalent		BocaRaton2018MRIPR844Needell	2019
2019-12-31	AstraZeneca UK Limited	$307	Research payment	In-kind items and services	LYNPARZA Drug, Oncology	Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy	2019
2019-12-31	Stryker Corporation	$234	Gift	Cash or cash equivalent	NONE Device, NONE		2019
2019-12-18	Merck Sharp & Dohme LLC	$2,342	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-12-18	Abbott Laboratories	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	AMPLATZER Occluders Device, Cardiac Arrhythmias and Heart Failure		2019
2019-12-17	AstraZeneca Pharmaceuticals LP	$1,636	Research payment	Cash or cash equivalent	IMFINZI Drug, Oncology	A Non-Interventional Primary Data Collection Study to Assess the Prevalence of PD-L1 High in First Line Metastatic and L	2019
2019-12-16	Eisai Inc.	$3,733	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$2,239	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$2,239	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$2,239	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$2,239	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$2,239	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$2,239	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$2,239	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-16	Eisai Inc.	$1,912	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-12-13	Clovis Oncology, Inc.	$1,626	Research payment	Cash or cash equivalent	Rubraca Drug, ONCOLOGY	A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene	2019
2019-12-13	Clovis Oncology, Inc.	$110	Research payment	Cash or cash equivalent	Rubraca Drug, ONCOLOGY	A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene	2019
2019-12-06	Merck Sharp & Dohme LLC	$32,478	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-12-03	Genentech, Inc.	$6,442	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE	2019
2019-12-03	Clovis Oncology, Inc.	$813	Research payment	Cash or cash equivalent	Rubraca Drug, ONCOLOGY	A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc	2019
2019-11-22	Bard Peripheral Vascular, Inc.	$7,500	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-11-22	Abbott Laboratories	$6,000	Research payment	Cash or cash equivalent	BurstDR Device, Cardiac Arrhythmias and Heart Failure	PROLONG Prospective, Multi-center, Open-label, Post-market Study (PROLONG)	2019
2019-11-22	Merck Sharp & Dohme LLC	$2,260	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-11-14	Stryker Corporation	$1,514	Research payment	Cash or cash equivalent	NEUROFORM EZ Device, STENT	HDE NEUROFORM	2019
2019-11-14	Stryker Corporation	$757	Research payment	Cash or cash equivalent	NEUROFORM EZ Device, STENT	HDE NEUROFORM	2019
2019-11-14	Stryker Corporation	$757	Research payment	Cash or cash equivalent	ATLAS Device, STENT	ATLAS	2019
2019-11-13	Abbott Laboratories	$990	Research payment	Cash or cash equivalent	BurstDR Device, Cardiac Arrhythmias and Heart Failure	PROLONG Prospective, Multi-center, Open-label, Post-market Study (PROLONG)	2019
2019-11-11	Cook Research Incorporated	$575	Research payment	Cash or cash equivalent	Cook Medical Advanced Tech Device, Aortic Intervention	Zenith p-Branch Endovascular Graft - Pivotal Study	2019
2019-11-07	Penumbra, Inc.	$20,000	Education	Cash or cash equivalent			2019
2019-10-31	Stryker Corporation	$1,560	Research payment	Cash or cash equivalent	NEUROFORM EZ Device, STENT	HDE NEUROFORM	2019
2019-10-28	Medical Device Business Services, Inc.	$10,000	Grant	Cash or cash equivalent			2019
2019-10-25	Allergan, Inc.	$5,000	Education	Cash or cash equivalent			2019
2019-10-25	Merck Sharp & Dohme LLC	$4,262	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-10-25	Merck Sharp & Dohme LLC	$1,000	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Randomized Phase 2 Study of the Combination of Pembrolizumab MK-3475 Plus Epacadostat INCB024360 with Platinum-based C	2019
2019-10-23	Merck Sharp & Dohme LLC	$18,187	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Randomized Phase 2 Study of the Combination of Pembrolizumab MK-3475 Plus Epacadostat INCB024360 with Platinum-based C	2019
2019-10-22	Merck Sharp & Dohme LLC	$492	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant The	2019
2019-10-22	Merck Sharp & Dohme LLC	$492	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant The	2019
2019-10-17	Stryker Corporation	$10,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	INFINITY Device, CATHETER		2019
2019-10-16	Medical Device Business Services, Inc.	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	MOUNTAINEER Device, Spine		2019
2019-10-14	Merck Sharp & Dohme LLC	$16,239	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-10-11	Penumbra, Inc.	$1,500	Education	Cash or cash equivalent			2019
2019-10-09	Stryker Corporation	$87	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2019
2019-10-09	Stryker Corporation	$78	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2019
2019-10-09	Stryker Corporation	$64	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2019
2019-10-09	Stryker Corporation	$35	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2019
2019-10-08	Genentech USA, Inc.	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-10-08	Merck Sharp & Dohme LLC	$48	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-10-08	Merck Sharp & Dohme LLC	$19	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-10-08	Merck Sharp & Dohme LLC	$15	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-10-08	Merck Sharp & Dohme LLC	$4	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-10-03	Abbott Laboratories	$1,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Cardiovascular- Research only Device, Cardiac Arrhythmias and Heart Failure		2019
2019-10-01	Genentech, Inc.	$6,132	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC	2019
2019-10-01	Genentech, Inc.	$2,195	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC	2019
2019-09-30	TESARO, Inc.	$2,700	Research payment	Cash or cash equivalent	ZEJULA Drug, ONCOLOGY	A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS	2019
2019-09-30	Endologix LLC	$1,267	Research payment	Cash or cash equivalent	Ovation Device, Cardiology/Vascular Diseases	Ovation PAS	2019
2019-09-30	Abbott Laboratories	$110	Research payment	In-kind items and services	BurstDR Device, Cardiac Arrhythmias and Heart Failure	PROLONG Prospective, Multi-center, Open-label, Post-market Study (PROLONG)	2019
2019-09-30	Abbott Laboratories	$110	Research payment	In-kind items and services	BurstDR Device, Cardiac Arrhythmias and Heart Failure	PROLONG Prospective, Multi-center, Open-label, Post-market Study (PROLONG)	2019
2019-09-26	GE HEALTHCARE	$50,400	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Device, MAMMOGRAPHY		2019
2019-09-26	GE HEALTHCARE	$22,866	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Device, MAMMOGRAPHY		2019
2019-09-25	Merck Sharp & Dohme LLC	$5,052	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-09-23	Pacira Pharmaceuticals Incorporated	$1,670	Research payment	In-kind items and services	EXPAREL Drug, PAIN MANAGEMENT	A MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A	2019
2019-09-19	GE HEALTHCARE	$5,310	Consulting Fee	Cash or cash equivalent	Device, MAMMOGRAPHY		2019
2019-09-19	GE HEALTHCARE	$2,752	Consulting Fee	Cash or cash equivalent	Device, MAMMOGRAPHY		2019
2019-09-18	Medtronic USA, Inc.	$9,287	Grant	Cash or cash equivalent			2019
2019-09-18	Medtronic USA, Inc.	$896	Grant	Cash or cash equivalent	ACTIVA Device, Deep Brain Neurostimulation		2019
2019-09-18	Medtronic USA, Inc.	$692	Grant	Cash or cash equivalent	ACTIVA Device, Deep Brain Neurostimulation		2019
2019-09-18	Medtronic USA, Inc.	$664	Grant	Cash or cash equivalent	ACTIVA Device, Deep Brain Neurostimulation		2019
2019-09-09	CSL Behring	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-09-06	ABBVIE INC.	$11,061	Research payment	Cash or cash equivalent		M12-914	2019
2019-08-27	Bard Peripheral Vascular, Inc.	$2,000	Education	Cash or cash equivalent			2019
2019-08-27	Genentech, Inc.	$465	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC	2019
2019-08-22	Bayer Healthcare Pharmaceuticals Inc.	$1,462	Research payment	Cash or cash equivalent	Non-Covered	BAY 1841788 mHSPC	2019
2019-08-21	Cook Research Incorporated	$54,652	Research payment	Cash or cash equivalent		Zenith p-Branch Endovascular Graft - Pivotal Study	2019
2019-08-21	Merck Sharp & Dohme LLC	$3,442	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-08-16	Cook Incorporated	$4,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-08-15	Stryker Corporation	$5,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	TREVO Device, MICROCATHETERSTENTRIEVER		2019
2019-08-12	Merck Sharp & Dohme LLC	$16,239	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-08-12	E.R. Squibb & Sons, L.L.C.	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	ELIQUIS Drug, Cardiovascular		2019
2019-08-10	Chiesi USA, Inc.	$1,062	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	CLEVIPREX Drug, CARDIOVASCULAR		2019
2019-08-09	Eisai Inc.	$4,457	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-08-08	Biocompatibles UK Ltd	$3,486	Research payment	Cash or cash equivalent	THERASPHERE - BIO Device, INTERVENTIONAL ONCOLOGY	QYF0001 TS 102 EPOCH	2019
2019-08-08	MDD US Operations, LLC	$1,666	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	MYOBLOC Biological, Neurology		2019
2019-08-08	MDD US Operations, LLC	$1,666	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	APOKYN Drug, Neurology		2019
2019-08-08	MDD US Operations, LLC	$1,666	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Xadago Drug, Neurology		2019
2019-08-08	Alexion Pharmaceuticals, Inc.	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	SOLIRIS Drug, Immunology		2019
2019-08-07	ABBVIE INC.	$817	Research payment	Cash or cash equivalent		M12-914	2019
2019-08-07	Abbott Laboratories	$118	Food and Beverage	In-kind items and services	AMPLATZER Occluders Device, Cardiac Arrhythmias and Heart Failure		2019
2019-08-07	Abbott Laboratories	$118	Food and Beverage	In-kind items and services	AMPLATZER Occluders Device, Cardiac Arrhythmias and Heart Failure		2019
2019-08-07	Abbott Laboratories	$118	Food and Beverage	In-kind items and services	AMPLATZER Occluders Device, Cardiac Arrhythmias and Heart Failure		2019
2019-08-07	Abbott Laboratories	$118	Food and Beverage	In-kind items and services	AMPLATZER Occluders Device, Cardiac Arrhythmias and Heart Failure		2019
2019-08-07	Abbott Laboratories	$118	Food and Beverage	In-kind items and services	AMPLATZER Occluders Device, Cardiac Arrhythmias and Heart Failure		2019
2019-07-29	GE HEALTHCARE	$63,000	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent			2019
2019-07-26	EMD Serono, Inc.	$13,349	Research payment	Cash or cash equivalent	MSB0011359C Biological, Oncology	MS200647-0005	2019
2019-07-26	Cook Incorporated	$4,000	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-07-25	Merck Sharp & Dohme LLC	$1,489	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Phase 3 Study of Pembrolizumab in Combination with Carboplatin,TaxanePaclitaxel or Nab-paclitaxel Followed by Pembroli	2019
2019-07-25	Merck Sharp & Dohme LLC	$213	Research payment	In-kind items and services	MK-7339 Drug, ONCOLOGY	A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizu	2019
2019-07-24	Merck Sharp & Dohme LLC	$8,317	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-23	Eisai Inc.	$1,650	Research payment	Cash or cash equivalent	Fycompa Drug, Neurology	A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Pat	2019
2019-07-22	GE HEALTHCARE	$67,689	Research payment	Cash or cash equivalent	Device, MAMMOGRAPHY	CLINICAL EVALUATION OF SENSEA PADDLE	2019
2019-07-22	CSL Behring	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-07-11	Endologix LLC	$585	Research payment	Cash or cash equivalent	Ovation Device, Cardiology/Vascular Diseases	Ovation PAS	2019
2019-07-10	Abbott Laboratories	$350	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	FreeStyle Lite system Device, Diabetes Care		2019
2019-07-10	Merck Sharp & Dohme LLC	$137	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$41	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$31	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$30	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$25	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$24	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$17	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$9	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-07-10	Merck Sharp & Dohme LLC	$1	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-06-24	TESARO, Inc.	$26,762	Research payment	In-kind items and services	ZEJULA Drug, ONCOLOGY	PHASE 2, MULTI-ARM STUDY OF NIRAPARIB ADMINISTERED ALONE AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH NON-SMAL	2019
2019-06-24	CSL Behring	$4	Education	In-kind items and services	Privigen Biological, Immunology		2019
2019-06-19	ABBVIE INC.	$1,627	Research payment	Cash or cash equivalent		M12-914	2019
2019-06-18	ABBVIE INC.	$1,025	Research payment	Cash or cash equivalent		M12-914	2019
2019-06-18	ABBVIE INC.	$817	Research payment	Cash or cash equivalent		M12-914	2019
2019-06-18	ABBVIE INC.	$817	Research payment	Cash or cash equivalent		M12-914	2019
2019-06-14	Merck Sharp & Dohme LLC	$16,239	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-06-11	GE HEALTHCARE	$43,847	Gift	Cash or cash equivalent	Device, ULTRASOUND		2019
2019-06-03	ABBVIE INC.	$1,528	Research payment	Cash or cash equivalent		M12-914	2019
2019-06-03	Genentech, Inc.	$1,182	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC	2019
2019-05-24	Merck Sharp & Dohme LLC	$2,097	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-05-16	Bayer Healthcare Pharmaceuticals Inc.	$1,462	Research payment	Cash or cash equivalent	Non-Covered	BAY 1841788 mHSPC	2019
2019-05-16	E.R. Squibb & Sons, L.L.C.	$500	Grant	Cash or cash equivalent			2019
2019-05-15	Verastem, Inc.	$13,176	Research payment	Cash or cash equivalent	Copiktra Drug, Hematology and Oncology	Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma	2019
2019-05-15	Genentech, Inc.	$4,856	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE	2019
2019-05-15	Verastem, Inc.	$1,245	Research payment	Cash or cash equivalent	Copiktra Drug, Hematology and Oncology	Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma	2019
2019-05-15	Verastem, Inc.	$1,100	Research payment	Cash or cash equivalent	Copiktra Drug, Hematology and Oncology	Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma	2019
2019-05-02	PFIZER INC.	$4,845	Research payment	Cash or cash equivalent	LORBRENA Drug, ONCOLOGY	A PHASE 3 RANDOMIZED OPENLABEL STUDY OF LORLATINIB PF06463922 MONOTHERAPY VERSUS CRIZOTINIB MONOTHERAPY IN THE FIRSTLINE	2019
2019-05-01	Cook Research Incorporated	$54,652	Research payment	Cash or cash equivalent		Zenith p-Branch Endovascular Graft - Pivotal Study	2019
2019-05-01	Amgen Inc.	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Aimovig Biological, Neuroscience		2019
2019-05-01	Clovis Oncology, Inc.	$813	Research payment	Cash or cash equivalent	Rubraca Drug, ONCOLOGY	A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene	2019
2019-04-30	KARL STORZ Endoscopy-America	$30	Gift	In-kind items and services	VITOM 90 DETACHABLE, AUTOCLAVE Device, MICRO/NOTES/MILITARY		2019
2019-04-30	KARL STORZ Endoscopy-America	$30	Gift	In-kind items and services	CONTAINER SYSTEM, FLEX FIBERSCOPES Device, CLEANING, STERILIZATION, CARE		2019
2019-04-27	Masimo Corporation	$123	Education	In-kind items and services	rainbow Acoustic Monitoring Device, Devices		2019
2019-04-12	Endologix LLC	$1,170	Research payment	Cash or cash equivalent	Ovation Device, Cardiology/Vascular Diseases	Ovation PAS	2019
2019-04-12	Stryker Corporation	$39	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2019
2019-04-12	Stryker Corporation	$17	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2019
2019-04-12	Stryker Corporation	$17	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2019
2019-04-12	Stryker Corporation	$15	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES		2019
2019-04-10	AstraZeneca UK Limited	$123,015	Research payment	Cash or cash equivalent	LYNPARZA Drug, Oncology	Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy	2019
2019-04-04	Genentech, Inc.	$2,402	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC	2019
2019-04-01	Bayer Healthcare Pharmaceuticals Inc.	$1,895	Research payment	Cash or cash equivalent	Non-Covered	BAY 1841788 mHSPC	2019
2019-04-01	Genentech, Inc.	$1,574	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC	2019
2019-03-29	KARL STORZ Endoscopy-America	$90	Gift	In-kind items and services	TELESCOPE, HOPKINS II, 0', 4MM DIAMETER Device, ENT		2019
2019-03-29	KARL STORZ Endoscopy-America	$30	Gift	In-kind items and services	TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY		2019
2019-03-29	KARL STORZ Endoscopy-America	$30	Gift	In-kind items and services	TELESCOPE, HOPKINS II, 0', 4MM DIAMETER Device, ENT		2019
2019-03-29	KARL STORZ Endoscopy-America	$30	Gift	In-kind items and services	TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY		2019
2019-03-21	Genentech, Inc.	$22,589	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC	2019
2019-03-21	Genentech, Inc.	$783	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	PH III OPEN LABEL STUDY ATEZO VS BSC FOLLOWING ADJUVANT CHEMO IN STAGE IB IIIA NSCLC	2019
2019-03-20	Merck Sharp & Dohme LLC	$4,802	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-03-18	PFIZER INC.	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	CHANTIX Drug, NEUROSCIENCE;TOBACCO DEPENDENCE		2019
2019-03-13	Cerner Corporation	$25	Consulting Fee	Cash or cash equivalent	Device, FetaLink Desktop		2019
2019-03-07	AstraZeneca Pharmaceuticals LP	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	FASENRA Drug, Respiratory		2019
2019-03-07	Insulet Corporation	$350	Compensation for services other than consulting, including serving as faculty or as a speaker at a v	Cash or cash equivalent	Omnipod Device, Insulin Pump		2019
2019-03-02	Boehringer Ingelheim Pharmaceuticals, Inc.	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-03-01	Genentech, Inc.	$11,646	Research payment	Cash or cash equivalent	TECENTRIQ Biological, BioOncology	A PHASE III OF ATEZOLIZUMAB PLUS ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER	2019
2019-02-28	Orthofix Medical, Inc.	$1,500	Consulting Fee	Cash or cash equivalent	Spinal-Stim Osteogenesis Stimulator Device, STIMULATOR, BONE GROWTH, NON-INVASIVE		2019
2019-02-26	Bayer Healthcare Pharmaceuticals Inc.	$1,462	Research payment	Cash or cash equivalent	Non-Covered	BAY 1841788 mHSPC	2019
2019-02-25	Genentech, Inc.	$9,344	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE	2019
2019-02-25	Merck Sharp & Dohme LLC	$5,415	Research payment	In-kind items and services	KEYTRUDA Biological, ONCOLOGY	A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy with or without Pembro	2019
2019-02-25	Merck Sharp & Dohme LLC	$2,565	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-02-19	Biocompatibles UK Ltd	$5,493	Research payment	Cash or cash equivalent	THERASPHERE - BIO Device, INTERVENTIONAL ONCOLOGY	QYF0001 TS 102 EPOCH	2019
2019-02-15	Medical Device Business Services, Inc.	$1,592	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	Mega Power Device, Energy		2019
2019-02-15	Allergan, Inc.	$1,500	Education	Cash or cash equivalent			2019
2019-02-15	Novartis Pharmaceuticals Corporation	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent			2019
2019-02-13	AstraZeneca Pharmaceuticals LP	$71,520	Research payment	Cash or cash equivalent	BRILINTA Drug, Cardiovascular and Metabolism	Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis TARGET TrialDoes Ticagrelor Improve Graft Patency	2019
2019-02-13	ABBVIE INC.	$390	Research payment	Cash or cash equivalent		M12-914	2019
2019-02-12	Merck Sharp & Dohme LLC	$8,590	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel,Nab-Paclitaxel Chemotherapy with or without Pembro	2019
2019-02-06	Merck Sharp & Dohme LLC	$10,108	Research payment	Cash or cash equivalent	KEYTRUDA Biological, ONCOLOGY	A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the	2019
2019-02-06	PFIZER INC.	$1,500	Space rental or facility fees (teaching hospital only)	Cash or cash equivalent	ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE		2019
2019-02-05	Genentech, Inc.	$7,910	Research payment	Cash or cash equivalent	Non-Covered Product Drug, None	PHASE III IPATASERTIB PLUS ABIRATERON IN MCRPC 1ST LINE	2019
2019-02-05	Eisai Inc.	$3,545	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-02-05	Eisai Inc.	$2,148	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-02-05	Eisai Inc.	$1,821	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-02-05	Eisai Inc.	$1,821	Research payment	Cash or cash equivalent	Lenvima Drug, Oncology	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination Wit	2019
2019-02-05	KARL STORZ Endoscopy-America	$120	Gift	In-kind items and services	HOPKINS II TELESCOPE, 0, 2.7MM X 18CM Device, ENT		2019
2019-02-05	KARL STORZ Endoscopy-America	$60	Gift	In-kind items and services	LIGHT CABLE, 3.5MM X 300CM. LGTH 9.8 FT Device, VIDEOIMAGING		2019
2019-02-04	KARL STORZ Endoscopy-America	$150	Gift	In-kind items and services	TELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY		2019
2019-02-04	KARL STORZ Endoscopy-America	$30	Gift	In-kind items and services	LIGHT CABLE, 3.5MM X 300CM. LGTH 9.8 FT Device, VIDEOIMAGING		2019
2019-01-31	TESARO, Inc.	$12,150	Research payment	Cash or cash equivalent	ZEJULA Drug, ONCOLOGY	A STUDY OF NIRAPARIB IN PATIENTS WITH OVARIAN CANCER WHO HAVE RECEIVED AT LEAST THREE PREVIOUS CHEMOTHERAPY REGIMENS	2019

The latest 200 records of 227.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.